FI20030958A0 - Nya föreningar - Google Patents

Nya föreningar

Info

Publication number
FI20030958A0
FI20030958A0 FI20030958A FI20030958A FI20030958A0 FI 20030958 A0 FI20030958 A0 FI 20030958A0 FI 20030958 A FI20030958 A FI 20030958A FI 20030958 A FI20030958 A FI 20030958A FI 20030958 A0 FI20030958 A0 FI 20030958A0
Authority
FI
Finland
Prior art keywords
compounds
formula
new compounds
andropause
sarm
Prior art date
Application number
FI20030958A
Other languages
English (en)
Finnish (fi)
Inventor
Jari Ratilainen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Priority to FI20030958A priority Critical patent/FI20030958A0/sv
Publication of FI20030958A0 publication Critical patent/FI20030958A0/sv
Priority to TW093117617A priority patent/TWI336321B/zh
Priority to AT04742130T priority patent/ATE464284T1/de
Priority to MEP-2008-865A priority patent/ME00522B/me
Priority to MXPA05013619A priority patent/MXPA05013619A/es
Priority to PCT/FI2004/000387 priority patent/WO2005000794A1/en
Priority to EP04742130A priority patent/EP1641745B1/en
Priority to ES04742130T priority patent/ES2343251T3/es
Priority to YU20050957A priority patent/RS52816B/sr
Priority to CA2529464A priority patent/CA2529464C/en
Priority to AU2004251900A priority patent/AU2004251900B2/en
Priority to BRPI0411939-8A priority patent/BRPI0411939A/pt
Priority to EA200600110A priority patent/EA012430B1/ru
Priority to US10/561,231 priority patent/US7390923B2/en
Priority to DE602004026583T priority patent/DE602004026583D1/de
Priority to UAA200600713A priority patent/UA86027C2/ru
Priority to PT04742130T priority patent/PT1641745E/pt
Priority to SI200431436T priority patent/SI1641745T1/sl
Priority to CL200401602A priority patent/CL2004001602A1/es
Priority to KR1020057024544A priority patent/KR20060035629A/ko
Priority to NZ543974A priority patent/NZ543974A/en
Priority to JP2006516233A priority patent/JP4809764B2/ja
Priority to DK04742130.0T priority patent/DK1641745T3/da
Priority to PL04742130T priority patent/PL1641745T3/pl
Priority to ARP040102263A priority patent/AR044934A1/es
Priority to IL172279A priority patent/IL172279A0/en
Priority to NO20060227A priority patent/NO332252B1/no
Priority to IS8256A priority patent/IS2752B/is
Priority to HRP20060036AA priority patent/HRP20060036B1/hr
Priority to HK07100331.1A priority patent/HK1093964A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
FI20030958A 2003-06-27 2003-06-27 Nya föreningar FI20030958A0 (sv)

Priority Applications (30)

Application Number Priority Date Filing Date Title
FI20030958A FI20030958A0 (sv) 2003-06-27 2003-06-27 Nya föreningar
TW093117617A TWI336321B (en) 2003-06-27 2004-06-18 Propionamide derivatives useful as androgen receptor modulators
PL04742130T PL1641745T3 (pl) 2003-06-27 2004-06-24 Pochodne propionoamidowe użyteczne jako modulatory receptora androgenowego
DE602004026583T DE602004026583D1 (de) 2003-06-27 2004-06-24 Als androgenrezeptormodulatoren geeignete propionamidderivate
UAA200600713A UA86027C2 (ru) 2003-06-27 2004-06-24 Производные пропионамида, полезные как модуляторы андрогенных рецепторов
MXPA05013619A MXPA05013619A (es) 2003-06-27 2004-06-24 Nuevos compuestos.
PCT/FI2004/000387 WO2005000794A1 (en) 2003-06-27 2004-06-24 Propionamide derivatives useful as androgen receptor modulators
EP04742130A EP1641745B1 (en) 2003-06-27 2004-06-24 Propionamide derivatives useful as androgen receptor modulators
ES04742130T ES2343251T3 (es) 2003-06-27 2004-06-24 Derivados de propionamida utiles como moduladores del receptor de androgenos.
YU20050957A RS52816B (sr) 2003-06-27 2004-06-24 Derivati propionamida koji se koriste kao modulatori androgenih receptora
CA2529464A CA2529464C (en) 2003-06-27 2004-06-24 Propionamide derivatives useful as androgen receptor modulators
AU2004251900A AU2004251900B2 (en) 2003-06-27 2004-06-24 Propionamide derivatives useful as androgen receptor modulators
BRPI0411939-8A BRPI0411939A (pt) 2003-06-27 2004-06-24 derivados de propionamida úteis como moduladores de receptores de androgênio
EA200600110A EA012430B1 (ru) 2003-06-27 2004-06-24 Производные пропионамида, полезные в качестве модуляторов андрогенных рецепторов
US10/561,231 US7390923B2 (en) 2003-06-27 2004-06-24 Propionamide derivatives useful as androgen receptor modulators
AT04742130T ATE464284T1 (de) 2003-06-27 2004-06-24 Als androgenrezeptormodulatoren geeignete propionamidderivate
MEP-2008-865A ME00522B (me) 2003-06-27 2004-06-24 Derivati propionamida koji se koriste kao modulatori androgenih receptora
PT04742130T PT1641745E (pt) 2003-06-27 2004-06-24 Derivados de propionamida úteis como moduladores do receptor de androgénio
SI200431436T SI1641745T1 (sl) 2003-06-27 2004-06-24 Propionamidni derivati, uporabni kot modulatorji androgenskega receptorja
CL200401602A CL2004001602A1 (es) 2003-06-27 2004-06-24 Compuestos no esteroidales derivados de propionanilida, moduladores del receptor androgenico con selectividad tisular (sarm); composicion farmaceutica; y uso en el tratamiento o prevencion de condiciones dependientes del receptor androgenico, como hi
KR1020057024544A KR20060035629A (ko) 2003-06-27 2004-06-24 안드로젠 수용체 모듈레이터로 유용한 프로피온아마이드유도체들
NZ543974A NZ543974A (en) 2003-06-27 2004-06-24 Propionamide derivatives useful as androgen receptor modulators
JP2006516233A JP4809764B2 (ja) 2003-06-27 2004-06-24 アンドロゲン受容体モジュレーターとして有用なプロピオンアミド誘導体
DK04742130.0T DK1641745T3 (da) 2003-06-27 2004-06-24 Propionamidderivater nyttige som androgenreceptormodulatorer
ARP040102263A AR044934A1 (es) 2003-06-27 2004-06-25 Derivados de propioanilidas, su uso como moduladores de receptores de androgenos. composiciones farmaceuticas.
IL172279A IL172279A0 (en) 2003-06-27 2005-11-30 Propionamide derivatives useful as androgen receptor modulators
NO20060227A NO332252B1 (no) 2003-06-27 2006-01-16 Propionamidderivater og farmasoytisk sammensetning anvendelig ved behandling eller forebygging av androgenmangel.
IS8256A IS2752B (is) 2003-06-27 2006-01-23 Própíónamíðafleiður@sem@eru@gagnlegar@sem@andrógenviðtakastillar
HRP20060036AA HRP20060036B1 (hr) 2003-06-27 2006-01-26 Derivati propionamida koji se koriste kao modulatori androgenih receptora
HK07100331.1A HK1093964A1 (en) 2003-06-27 2007-01-10 Propionamide derivatives useful as androgen receptor modulators

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20030958A FI20030958A0 (sv) 2003-06-27 2003-06-27 Nya föreningar

Publications (1)

Publication Number Publication Date
FI20030958A0 true FI20030958A0 (sv) 2003-06-27

Family

ID=8566309

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20030958A FI20030958A0 (sv) 2003-06-27 2003-06-27 Nya föreningar

Country Status (21)

Country Link
US (1) US7390923B2 (sv)
EP (1) EP1641745B1 (sv)
JP (1) JP4809764B2 (sv)
AT (1) ATE464284T1 (sv)
AU (1) AU2004251900B2 (sv)
BR (1) BRPI0411939A (sv)
CA (1) CA2529464C (sv)
CL (1) CL2004001602A1 (sv)
DK (1) DK1641745T3 (sv)
EA (1) EA012430B1 (sv)
ES (1) ES2343251T3 (sv)
FI (1) FI20030958A0 (sv)
ME (1) ME00522B (sv)
NZ (1) NZ543974A (sv)
PL (1) PL1641745T3 (sv)
PT (1) PT1641745E (sv)
RS (1) RS52816B (sv)
SI (1) SI1641745T1 (sv)
TW (1) TWI336321B (sv)
UA (1) UA86027C2 (sv)
WO (1) WO2005000794A1 (sv)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7205437B2 (en) * 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US8445534B2 (en) 2000-08-24 2013-05-21 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US8008348B2 (en) 2001-12-06 2011-08-30 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US7253210B2 (en) 2002-10-15 2007-08-07 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US8853266B2 (en) 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
AU2002364949C1 (en) 2001-12-06 2008-05-29 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
TW200533636A (en) 2003-12-16 2005-10-16 Gtx Inc Prodrugs of selective androgen receptor modulators and methods of use thereof
AP2006003700A0 (en) 2004-02-13 2006-08-31 Warner Lambert Co Androgen receptor modulators
CA2563291A1 (en) * 2004-04-13 2005-10-27 Warner-Lambert Company Llc 4-cyano-phenoxy-alkyl carboxyl derivatives as androgen modulators
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
GEP20094851B (en) * 2004-06-07 2009-12-10 The Univ Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
BRPI0513020A (pt) 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
EP1991523B1 (en) * 2006-03-03 2012-08-15 Orion Corporation Selective androgen receptor modulators
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
CA2799183A1 (en) 2010-05-12 2011-11-17 Radius Health, Inc. Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
FR2982261B1 (fr) 2011-11-04 2014-06-13 Galderma Res & Dev Nouveaux amides, et leur utilisation pharmaceutique ou cosmetique
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
EP3733170A1 (en) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
CA2943611A1 (en) 2014-03-28 2015-10-01 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
US20160106702A1 (en) * 2014-10-16 2016-04-21 Gtx, Inc. METHODS OF TREATING UROLOGICAL DISORDERS USING SARMs
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) * 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
KR20170138536A (ko) * 2015-04-21 2017-12-15 지티엑스, 인코포레이티드 선택적 안드로겐 수용체 분해제(sard) 리간드 및 이의 사용 방법
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CN107709290B (zh) 2015-04-21 2023-02-28 Gtx公司 选择性雄激素受体降解剂(sard)配体和其使用方法
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
KR102397890B1 (ko) 2016-06-22 2022-05-12 일립시스 파마 리미티드 Ar+ 유방암 치료 방법
KR102322802B1 (ko) 2017-01-05 2021-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
IL279853B1 (en) 2018-07-04 2024-09-01 Radius Pharmaceuticals Inc Polymorphic forms of RAD 1901-2HCL
WO2020051260A1 (en) * 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
WO2020073017A1 (en) * 2018-10-05 2020-04-09 University Of Tennesse Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
US6995284B2 (en) * 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
EA014224B1 (ru) * 2000-08-24 2010-10-29 Юниверсити Оф Теннесси Рисерч Фаундейшн Селективные модуляторы андрогенового рецептора и способы их применения
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
AU2002364949C1 (en) 2001-12-06 2008-05-29 University Of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators
BRPI0307699A2 (pt) 2002-02-07 2015-06-16 Gtx Inc Tratamento de hiperplasia benigna da próstata com sarms.
US7022870B2 (en) * 2002-06-17 2006-04-04 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
JP2006505563A (ja) * 2002-10-15 2006-02-16 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体調節剤による肥満治療
WO2004035739A2 (en) * 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
EP1592658B1 (en) * 2003-01-13 2013-04-24 University of Tennessee Research Foundation Large-scale synthesis of selective androgen receptor modulators
AU2004206909A1 (en) * 2003-01-22 2004-08-05 Gtx Inc. Treating androgen deficiency in female (ADIF)-associated conditions with sarms

Also Published As

Publication number Publication date
CL2004001602A1 (es) 2005-05-20
DK1641745T3 (da) 2010-07-26
ME00522B (me) 2011-10-10
CA2529464A1 (en) 2005-01-06
RS20050957A (en) 2008-04-04
UA86027C2 (ru) 2009-03-25
EP1641745A1 (en) 2006-04-05
ATE464284T1 (de) 2010-04-15
JP4809764B2 (ja) 2011-11-09
US20070123512A1 (en) 2007-05-31
WO2005000794A1 (en) 2005-01-06
AU2004251900A1 (en) 2005-01-06
ES2343251T3 (es) 2010-07-27
EA200600110A1 (ru) 2006-06-30
TWI336321B (en) 2011-01-21
US7390923B2 (en) 2008-06-24
SI1641745T1 (sl) 2010-07-30
PL1641745T3 (pl) 2010-09-30
EA012430B1 (ru) 2009-10-30
BRPI0411939A (pt) 2006-08-15
NZ543974A (en) 2009-04-30
PT1641745E (pt) 2010-05-25
AU2004251900B2 (en) 2009-10-22
CA2529464C (en) 2012-01-03
TW200505419A (en) 2005-02-16
EP1641745B1 (en) 2010-04-14
RS52816B (sr) 2013-10-31
JP2007520425A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
FI20030958A0 (sv) Nya föreningar
MX2007004699A (es) Derivados de indol y bencimidazol.
MY151295A (en) Pyrimidyl indoline compound
SG10201809390QA (en) Modulators of indoleamine 2,3-dioxygenase and methods of using the same
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
TW200612958A (en) Substituted imidazole derivatives
WO2007117465A3 (en) Indazole compounds
EA200900213A1 (ru) Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич
MY152271A (en) Novel compounds that are erk inhibitors
WO2007084728A3 (en) 2-imino-benzimidazoles
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
JO3602B1 (ar) مركبات بنزيميدازول بصفتها منظمات لمستقبلات في ار 1
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
MX2013004162A (es) Composiciones farmaceuticas que contienen un inhibidor de dgat1.
IL193252A0 (en) N-hydroxyacrylamide compounds
MY153763A (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
EA201071183A1 (ru) Безводная кристаллическая форма малеата орвепитанта
MX2013002620A (es) Novedosas n-hidroxi-benzamidas para el tratamiento del cancer.
MX2012004835A (es) Derivados de espirolactama y usos de los mismos.
MX2009013003A (es) Derivados de piperidina-amida.
TW200720273A (en) Pharmaceutically active spiro-benzimidazoles
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
IL206570A (en) 4,3-Dihydro Compound-1 h- Isoquinoline is converted into 3 positions, process for preparation and use
MXPA05013619A (es) Nuevos compuestos.
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
FD Application lapsed

Free format text: FI 6490